BetterWay Blood Testing by Babson Diagnostics Brings Convenient, Affordable Blood Testing to SXSW
AUSTIN, Texas--(BUSINESS WIRE)--Feb 25, 2025--
BetterWay™ blood testing by Babson Diagnostics is excited to bring its innovative blood testing technology to the 2025 SXSW ® Conference and Festivals, a gathering of the world's foremost innovators, creatives, and thought leaders across industries. SXSW attendees can experience firsthand how BetterWay has reimagined blood testing to make it friendly, convenient, and affordable without sacrificing the accuracy and efficiency of laboratory analysis.
BetterWay is a unique blood testing service where pea-sized samples are collected from the fingertip at convenient locations and analyzed at Babson's CLIA-certified laboratory in Austin. This enables a less-invasive alternative to venipuncture for a broad range of routine diagnostic tests.
Babson launched BetterWay in May 2024 at retail pharmacies in Austin after years of research and development, including 45 clinical studies to validate the technologies and demonstrate test result accuracy. In December 2024, Babson also launched BetterWay for Healthcare Organizations to enable health systems to lower barriers to testing, close gaps in care, and improve patient satisfaction. SXSW recognized Babson's cutting-edge approach to an essential medical service by naming BetterWay a finalist for its 2025 Innovation Awards.
As an Austin-based company, Babson Diagnostics is honored to be involved in its hometown's inspiring, dynamic conference. 'SXSW is all about new ideas, and this is your chance to experience the future of blood testing,' said Eric Olson, founder and chief operating officer of Babson Diagnostics. 'Bringing BetterWay to SXSW demonstrates how we're making blood testing convenient and accessible, whether at a doctor's office, a neighborhood pharmacy, or even in the heart of a major festival.'
BetterWay will be available at multiple events during SXSW starting on March 8, allowing attendees to seamlessly integrate health screenings into their festival experience. They will receive easy-to-understand test results in one to two days. BetterWay is offering a $25 discount to all attendees, which covers tests such as a comprehensive metabolic panel or lipid panel. Attendees can pre-book appointments by texting 'SXSW' to BetterWay Customer Support at (512) 877-8770 or simply walk up at the events listed below.
SXSW Innovation Awards Finalist Showcase
Location: JW Marriott, Griffin Hall – 110 E. 2 nd St.
Location: JW Marriott, Griffin Hall – 110 E. 2 nd St.
Date & Time: Saturday, March 8 | 2 to 5 p.m.
The SXSW Innovation Awards celebrate a variety of technological advancements and discoveries. BetterWay is one of five finalists in the Health & Biotech category. At the showcase, all 55 finalists across 11 categories will have the opportunity to demonstrate their innovations. Contest judges will determine the winner for each category, and SXSW badge holders will determine the winner for the People's Choice Award.
SXSW Expo
Location: Austin Convention Center – 500 E. Caesar Chavez St.
Location: Austin Convention Center – 500 E. Caesar Chavez St.
Date & Time: Sunday, March 9 - Wednesday, March 12 | 9 a.m. to 4 p.m.
Visit Booth 633 in the Health + Wellness pavilion to see BetterWay in action, meet the team, and get tested. The Expo will be open to the public on Wednesday.
Eating for a Healthier, Happier Life: The Transformative Power of Clean Eating
Location: The Well – 440 W. 2 nd St.
Location: The Well – 440 W. 2 nd St.
Date & Time: Monday, March 10 | 2:30 to 5 p.m.
BetterWay will be part of a panel moderated by Everguide Health CEO Cindy Stefanko and featuring functional medicine nutritionist Lauren Embree, Nova Hospitality CEO Jack Zimmerman, and Austin Chef Vanessa Musi to discuss intentional eating and how diet affects health. A BetterWay representative will discuss how blood testing can help people track their lifestyle changes and take proactive steps to improve their health. Testing will not be available at this event, but attendees can still access a $25 discount toward future tests.
KUTX Live! At Scholz Garten
Location: Scholz Garten – 1607 San Jacinto Blvd.
Location: Scholz Garten – 1607 San Jacinto Blvd.
Date & Time: Wednesday, March 12 - Saturday, March 15 | 8 a.m. to noon
Testing will be available on Friday and Saturday. On Wednesday and Thursday, representatives will be available to discuss how BetterWay can provide actionable data to support wellness journeys.
About BetterWay by Babson Diagnostics
BetterWay is blood testing reimagined—affordable fingertip collection at convenient locations with fast, accurate lab results. Available now at Austin pharmacies and clinics, BetterWay empowers people to take charge of their health. Customers can order for themselves or with a doctor and receive clear, easy-to-understand results in one to two days. BetterWay was developed by Babson Diagnostics, a science-first healthcare technology company named 2024 Medtech Company of the Year by MD + DI. Healthcare organizations across the US can partner with Babson to bring the BetterWay experience to their patients. For more information, please visit betterway.com or connect with us on Instagram or LinkedIn.
SOURCE: Babson Diagnostics
Copyright Business Wire 2025.
PUB: 02/25/2025 11:03 AM/DISC: 02/25/2025 11:03 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 minutes ago
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Yahoo
42 minutes ago
- Yahoo
National Advertising Division Finds Certain Boxed Water is Better® Environmental Claims Supported; Recommends Others be Modified or Discontinued
In a challenge brought by the International Bottled Water Association, BBB National Programs' National Advertising Division determined that Boxed Water is Better®, which markets and sells purified water in plant-based cartons, provided a reasonable basis for challenged recyclability, tree planting, and certain environmental impact claims. New York, NY, June 06, 2025 (GLOBE NEWSWIRE) -- In a challenge brought by the International Bottled Water Association, BBB National Programs' National Advertising Division determined that Boxed Water is Better®, which markets and sells purified water in plant-based cartons, provided a reasonable basis for challenged recyclability, tree planting, and certain environmental impact claims. However, the National Advertising Division (NAD) recommended that Boxed Water is Better modify or discontinue other claims related to renewable materials and sustainable sourcing. During the proceeding, Boxed Water is Better voluntarily agreed to modify certain environmental comparison claims and permanently discontinue certain comparative environmental claims. Therefore, NAD did not review these claims on their merits and will treat them, for compliance purposes, as though NAD recommended they be modified or discontinued. Recyclability Claims In support of claims that its cartons are 'Recyclable' and '100% Recyclable,' Boxed Water is Better explained that each carton of Boxed Water contains only three materials: fiber, aluminum, and plant-based plastic, and 100% of these materials are recyclable. It was undisputed that 100% of the Boxed Water carton is able to be recycled, provided the facility separates the layers and has the capacity. Therefore, NAD concluded that Boxed Water is Better provided a reasonable basis for its recyclability claims. Renewable Materials Claims In support of its '92% plant-based carton' and 'our carton is made from 92% renewable materials' claims, Boxed Water is Better explained that the liner film and the cap are 100% plant-based plastic as determined through a mass balance accounting approach (a method to track the sourcing of renewable materials when mixed with non-renewable materials in production even where any individual carton may not physically contain the claimed amount of renewable material). NAD noted that some consumers may not know of mass balance and instead may reasonably expect the claim to mean that each carton physically contains 92% renewable materials. Therefore, NAD recommended Boxed Water is Better modify these claims to clarify how their calculations are done. Additionally, NAD recommended that Boxed Water is Better modify the unqualified renewable claim 'Explore our renewable packaged option' by disclosing the amount of renewable materials in the cartons, and discontinue the claim 'For those times when reusable bottles aren't an option, our paper-based cartons are the most renewable option in the water aisle' as the evidence was not sufficient to support this superiority claim. General Environmental Benefit and Sustainability Claims Given the context in which the challenged claims appear on the Boxed Water is Better website, NAD concluded that many of the Boxed Water is Better carton claims, including 'The earth loves our box,' 'Better for the Planet,' and 'Sustainable' are not unqualified general environmental benefit claims and do not require additional qualification. However, NAD recommended that Boxed Water is Better modify its 'Sustainably sourced' claim by clearly and conspicuously explaining what the claim means. Life Cycle Analysis Claims During the challenge, Boxed Water is Better agreed to permanently modify certain claims to make clear that the comparison is to premium plastic bottles, including 'Boxed Water is Better,' 'Boxed Water is better than plastic,' and 'Compared to single-use plastic bottles and canned water, our plant-based cartons have a lower environmental impact throughout their lifecycle.' In support of these and similar claims, Boxed Water is Better submitted a Life Cycle Analysis comparing the environmental impact of a carton of Boxed Water to a model premium plastic water bottle and a model aluminum can of water. Based on the results, NAD concluded that Boxed Water is Better provided a reasonable basis for its comparative environmental impact claims, including 'Boxed Water is better than aluminum.' Tree-Planting Claims NAD concluded that Boxed Water is Better's evidence of the number of trees planted sufficiently supports its claims that it planted 1.5 million trees. Other Claims NAD concluded that Boxed Water is Better's advertising did not reasonably convey the challenged messages that Boxed Water is Better cartons are made with 100% plant-based materials and that the cartons are biodegradable. The International Bottled Water Association stated that it will request review of NAD's decision by the National Advertising Review Board (NARB), the appellate-level truth-in-advertising body of BBB National Programs. In its advertiser statement, Boxed Water is Better stated that it 'will follow NAD's recommendations' and 'thanks NAD for its careful analysis.' All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for advertising or promotional purposes. About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, promote fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and promoting fair competition for business. CONTACT: Name: Jennie Rosenberg Email: jrosenberg@ Job Title: Media Relations
Yahoo
an hour ago
- Yahoo
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Spectral's seven director nominees were elected: Nominee Votes For (percent) Votes Withheld (percent) Jan D'Alvise 99.78% 0.22% Jun Hayakawa 99.79% 0.21% Chris Seto 89.39% 10.61% William Stevens 99.50% 0.50% Paul Walker 97.67% 2.33% David W. Feigal, Jr. 99.67% 0.33% Cristiano Franzi 99.78% 0.22% Appointment of Auditors MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral. Votes For: 99.95% Votes Withheld: 0.05% About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis The trial methods are detailed in 'Bayesian methods: a potential path forward for sepsis trials'. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company's ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter's commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali MahdaviCapital Markets & Investor RelationsSpinnaker Capital Markets Inc.416-962-3300am@
